Hepatitis surface B antigen clearance induced by long-term tenofovir disoproxil fumarate monotherapy in chronic hepatitis B treatment: a meta-analysis and longitudinal modeling analysis

• Published in: Virology journal Vol. 22; no. 1; p. 158
• Main Authors: Jian, Weizhe, Yin, Yalin, Xue, Junsheng, Chen, Rong, Feng, Jingwen, Zeng, Jiayao, He, Ruoyi, Zhou, Tianyan
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22.05.2025; BMC
• Subjects: Antigens; Antiviral Agents - therapeutic use; CHB; chronic hepatitis B; DNA; Dosage and administration; Drug therapy; fumarates; HBsAg clearance; HBsAg seroconversion; Hepatitis B; hepatitis B antigens; Hepatitis B Surface Antigens - blood; Hepatitis B virus; Hepatitis B virus - drug effects; Hepatitis B virus - immunology; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - virology; Humans; Immune response; Longitudinal Studies; Medical research; Medicine, Experimental; meta-analysis; Model-based simulation; Physiological aspects; seroconversion; simulation models; systematic review; TDF; Tenofovir; Tenofovir - therapeutic use; therapeutics; Treatment Outcome; China; HBsAg clearance; Model-based simulation; CHB; HBsAg seroconversion; TDF

Chronic hepatitis B (CHB) is a significant global health challenge, with tenofovir disoproxil fumarate (TDF) widely used as an effective treatment option. Despite TDF's efficacy in suppressing hepatitis B virus (HBV) DNA, it rarely achieves functional cure, requiring hepatitis B surface antigen...